Added by |
pmartino |
Group name |
EquipePM |
Item Type |
Journal Article |
Title |
Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients |
Creator |
Honoré et al. |
Author |
C. Honoré |
Author |
J. B. Delhorme |
Author |
E. Nassif |
Author |
M. Faron |
Author |
G. Ferron |
Author |
E. Bompas |
Author |
O. Glehen |
Author |
A. Italiano |
Author |
F. Bertucci |
Author |
D. Orbach |
Author |
M. Pocard |
Author |
F. Quenet |
Author |
J. Y. Blay |
Author |
S. Carrere |
Author |
C. Chevreau |
Author |
O. Mir |
Author |
A. Le Cesne |
Abstract |
BACKGROUND: Despite being associated with a very poor prognosis, long-term survivors across all series of Desmoplastic Small Round Cell Tumor (DSRCT) have been reported.
AIM OF THE STUDY: To analyze patients 'characteristics associated with a prolonged survival after DSRCT diagnosis.
METHODS: All consecutive patients treated for DSRCT in nine French expert centers between 1991 and 2018 were retrospectively analyzed. Patients with a follow-up of less than 2 years were excluded and cure defined as being disease-free at least 5 years.
RESULTS: 100?pts were identified (median age 25 years, 89% male). 27 had distant metastases at diagnosis and 80?pts underwent upfront chemotherapy (CT). 71?pts were operated, 20?pts without prior CT). Surgery was macroscopically complete (CC0/1) in 50?pts. Hyperthermic intraperitoneal Chemotherapy (HIPEC) was administered during surgery in 15?pts 54?pts had postoperative CT and 26?pts had postoperative whole abdomino-pelvic RT (WAP-RT). After a median follow-up of 103 months (range 23-311), the median overall survival (OS) was 25 months. The 1- year, 3-year and 5-year OS rates were 90%, 35% and 4% respectively. 5 patients were considered cured after a median disease-free interval of 100 months (range 22-139). Predictive factors of cure were female sex (HR?=?0.49, p?=?0.014), median PCI<12 (HR?=?0.32, p?=?0.0004), MD Anderson stage I (HR?=?0.25, p?0.0001), CC0/1 (HR?=?0.34, p?0.0001), and WAP-RT (HR?=?0.36, p?=?0.00013). HIPEC did not statistically improve survival.
CONCLUSION: Cure in DSRCT is possible in 5% of patients and is best achieved combining systemic chemotherapy, complete cytoreductive surgery and WAP-RT. Despite aggressive treatment, recurrence is common and targeted therapies are urgently needed. |
Publication |
Surgical Oncology |
Volume |
29 |
Pages |
107-112 |
Date |
Jun 2019 |
Journal Abbr |
Surg Oncol |
Language |
eng |
DOI |
10.1016/j.suronc.2019.04.002 |
ISSN |
1879-3320 |
Short Title |
Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? |
Library Catalog |
PubMed |
Extra |
00000
PMID: 31196472 |
Tags |
Adolescent, Adult, Chemotherapy, Chemotherapy, Cancer, Regional Perfusion, Child, Child, Preschool, clinic, Combined Modality Therapy, Cure, Cytoreduction Surgical Procedures, Desmoplastic Small Round Cell Tumor, Female, Follow-Up Studies, Humans, Hyperthermia, Induced, Male, Middle Aged, Patient Selection, Peritoneal Neoplasms, Prognosis, Retrospective Studies, Surgery, Survival, Survival Rate, Young Adult |
Date Added |
2020/01/03 - 10:24:11 |
Date Modified |
2020/01/03 - 10:24:30 |
Notes and Attachments |
PubMed entry (Attachment) |